One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

Allurion catapulted nearly 200% early Friday after the company said it plans to test its weight-loss technology with an ...

BofA Securities maintained a Buy rating on Eli Lilly stock (NYSE:LLY), with a price target set at $997.00. With a market capitalization of $706 billion and impressive revenue growth of 27.4% over the ...

Generally, you can count on drugmakers for a steady revenue performance -- since patients need their medicines, revenue holds ...

Novo Nordisk's phase 1b/2a clinical trial results revealed that their investigational drug, amycretin, led to an average ...

The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.

We now have two FDA-approved disease-modifying treatments for Alzheimer's disease, and hundreds of clinical trials are ...

AnalytiXIN has launched a consortium designed to give Indiana researchers better access to health care data—potentially ...

Novo Nordisk (NVO) stock jumped 12% in pre-market trading Friday after it released promising results of an early-stage weight ...

Novo Nordisk (NVO) stock gains on promising Phase 1/2 data for the drugmaker's new weight loss drug amycretin. Read more here ...

Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new drug last month and ...

The nature of the beast is yes, these drugs come off patent; the demand is there and someone could produce it more cheaply’, ...